Pfizer Inc. (PFE)
Pfizer (PFE) Gains As Market Dips: What You Should Know
The latest trading day saw Pfizer (PFE) settling at $29.21, representing a +2.96% change from its previous close.
Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stock is at $249.55, down 5% early in the session. The company raised its full-year outlook in the same release that showed its reported profit falling under one-time charges.
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock?
PFE moves above its 50-day SMA as newer drugs, oncology and obesity treatments fuel growth prospects, but declining COVID sales and patent expirations pose challenges.
Pfizer's Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning
Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer: Previously Bearish, I'm Converting To A Cautious Bull (Rating Upgrade)
Pfizer's stronger non-COVID outlook more than offsets lower COVID revenue expectations, although full-year revenue guidance still implies a decline. Pfizer expects another $2.7B in cost savings through 2029, potentially improving operating margins. Patent expirations, pricing pressure and recurring impairment charges could offset Pfizer's cost savings and constrain profitability.
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results
PFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage pipeline.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer
Pfizer's Tukysa combo regimen wins FDA approval for frontline maintenance breast cancer treatment, extending its use beyond the second-line setting.
Pfizer's Yield Is Three Times Bigger. Johnson & Johnson's Dividend Has Something Pfizer Does Not
Pfizer's yield towers over Johnson and Johnson's, but a bigger number on paper can hide serious risks underneath. Before you chase that payout, consider what a frozen dividend, rising debt, and a multibillion-dollar write-down actually signal about income reliability.
PFE vs. JNJ: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Johnson & Johnson (JNJ). But which of these two stocks offers value investors a better bang for their buck right now?
Are Investors Undervaluing Pfizer (PFE) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
